通心络胶囊联合美托洛尔治疗冠心病室性心律失常的临床疗效观察

Clinical Effect of Tongxinluo Capsules Combined with Metoprolol in Treating Coronary Heart Disease Patients Complicated with Ventricular Arrhythmia

目的观察通心络胶囊联合美托洛尔治疗冠心病室性心律失常的临床疗效。方法选取中国海洋石油南海西部医院心血管内科2014年9月—2015年9月收治的冠心病室性心律失常患者300例,根据随机化原则分为对照组和观察组,每组150例。在常规治疗基础上,对照组患者给予美托洛尔口服,观察组患者在对照组基础上给予通心络胶囊口服;两组患者均连续治疗4个月。比较两组患者临床疗效,治疗前后心功能指标〔包括左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)及左心室射血分数(LVEF)〕及心律失常发生情况(包括室性期前收缩发作频率、房室交界性期前收缩发作频率及房性期前收缩发作频率),记录两组患者治疗期间不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前两组患者LVEDD、LVESD、LVEF比较,差异无统计学意义(P>0.05);治疗后观察组患者LVEDD、LVESD短于对照组,LVEF高于对照组(P<0.05)。治疗前两组患者室性期前收缩发作频率、房室交界性期前收缩发作频率、房性期前收缩发作频率比较,差异无统计学意义(P>0.05);治疗后观察组患者室性期前收缩发作频率、房室交界性期前收缩发作频率、房性期前收缩发作频率低于对照组(P<0.05)。治疗期间两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论通心络胶囊联合美托洛尔治疗冠心病室性心律失常的临床疗效确切,可有效改善患者心功能并减少心律失常的发生,且安全性较高。

Objective To observe the clinical effect of tongxinluo capsules combined with metoprolol in treating coronary, heart disease patients complicated with ventricular arrhythmia. Methods From September 2014 to September 2015, a total of 300 coronary heart disease patients complicated with ventrieular arrhythmia were selected in the Department of Cardiovascular Medicine, Western South China Sea HoSpital of China National Offshore Oil Corporation, and they were randomly divided into control group and observation group, each of 150 cases. Based on conventional treatment, patients of control group were given metoprolol, while patients of observation group were given tongxinluo capsules combined with metoprolol; both groups continuously treated for 4 months. Clinical effect, index of cardiac function （ including LVEDD, LVESD and LVEF ） and incidence of arrhythmia （including ventricular premature contraction attack frequency, atrioventricular junctional premature contraction attack frequency and atrial premature contraction attack frequency） before and after treatment, and incidence of adverse reactions during the treatment were compared between the two groups. Results The clinical effect of observation group was statistically significantly better than that of control group （ P 〈 0.05 ）. No statistically significant differences of LVEDD, LVESD or LVEF was found between the two groups before treatment （P 〉 0. 05） ; after treatment, LVEDD and LVESD of observation group were statistically significantly shorter than those of control group, while LVEF of observation group was statistically significantly higher than that of control group （ P 〈 0. 05 ）. No statistically significant differences of ventricular premature contraction attack frequency, atrioventricular junctional premature contraction attack frequency or atrial prematurecontraction attack frequency was found between the two groups before treatment （P 〉 0.05 ）, while ventricular premature contraction attack frequency, atrioventricular junctional premature contraction attack frequency and atrial premature contraction attack frequency of observation group were statistically significantly lower than those of control group after treatment （P 〈 0. 05 ）. No statistically significant differences of incidence of adverse reactions was found between the two groups during the treatment （ P 〉0. 05）. Conclusion Tongxinluo capsules combined with metoprolol has certain clinical effect in treating coronary heart disease patients complicated with ventricular arrhythmia, can effectively improve the cardiac function and reduce the incidence of arrhythmia, with relatively high safety.